|
| 35961518 | UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis. | Clin Gastroenterol Hepatol | 2023 |
| 37191344 | Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis. | Gut Microbes | 2023 |
| 37026715 | Regulation of immune responses in primary biliary cholangitis: a transcriptomic analysis of peripheral immune cells. | Hepatol Commun | 2023 |
| 36470304 | FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. | Nature | 2023 |
| 36639314 | Corrigendum to: "An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs" [J Hepatol 75 (2021) 572-581]. | J Hepatol | 2023 |
| 36243043 | Anti-Cholestatic Therapy with Obeticholic Acid Improves Short-Term Memory in Bile Duct-Ligated Mice. | Am J Pathol | 2023 |
| 34864633 | rs9459874 and rs1012656 in CCR6/FGFR1OP confer susceptibility to primary biliary cholangitis. | J Autoimmun | 2022 |
| 35609437 | The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study. | EBioMedicine | 2022 |
| 35500149 | Commentary on "Genome-wide meta-analysis identifies novel susceptibility loci for autoimmune hepatitis type 1". | Hepatology | 2022 |
| 35686197 | The National Audit of Primary Biliary Cholangitis (PBC) in the United Kingdom: Defining the Audit Dataset and Data Collection System. | Cureus | 2022 |
| 36818800 | UK-PBC National Audit: a collaborative success in identifying critical shortfalls. | Frontline Gastroenterol | 2022 |
| 36523650 | Neurosteroid Activation of GABA-A Receptors: A Potential Treatment Target for Symptoms in Primary Biliary Cholangitis? | Can J Gastroenterol Hepatol | 2022 |
| 36150526 | Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls. | Gastroenterology | 2022 |
| 32562892 | Effects of Primary Biliary Cholangitis on Quality of Life and Health Care Costs in the United Kingdom. | Clin Gastroenterol Hepatol | 2021 |
| 33602855 | Cholangiocyte organoids can repair bile ducts after transplantation in the human liver. | Science | 2021 |
| 33821150 | Assessing efficacy of hepatocellular carcinoma prediction scores to prioritise hepatitis B surveillance in the COVID-19 era. | GastroHep | 2021 |
| 33554101 | Quality of life in patients with primary biliary cholangitis: A cross-geographical comparison. | J Transl Autoimmun | 2021 |
| 34129689 | The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis. | Hepatology | 2021 |
| 33035628 | Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. | J Hepatol | 2021 |
| 32851498 | Understanding Fatigue in Primary Biliary Cholangitis. | Dig Dis Sci | 2021 |
| 32446714 | High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry. | J Hepatol | 2020 |
| 31757316 | Individualizing Care: Management Beyond Medical Therapy. | Surg Oncol Clin N Am | 2020 |
| 31850579 | Editorial: rapid assessment of health-related quality of life in primary biliary cholangitis-no excuse not to ask. Authors' reply. | Aliment Pharmacol Ther | 2020 |
| 31850571 | Letter: histology is relevant for risk stratification in primary biliary cholangitis. | Aliment Pharmacol Ther | 2020 |
| 30557739 | Pruritus Is Common and Undertreated in Patients With Primary Biliary Cholangitis in the United Kingdom. | Clin Gastroenterol Hepatol | 2019 |
| 31664722 | PBC-10: a short quality of life measure for clinical screening in primary biliary cholangitis. | Aliment Pharmacol Ther | 2019 |
| 30566748 | Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System. | Hepatology | 2019 |
| 29663477 | The Impact of Autoimmune Hepatitis and Its Treatment on Health Utility. | Hepatology | 2018 |
| 30017646 | Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. | Lancet Gastroenterol Hepatol | 2018 |
| 29881820 | Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis. | Hepatol Commun | 2018 |
| 30119881 | Increased sensitivity of Treg cells from patients with PBC to low dose IL-12 drives their differentiation into IFN-γ secreting cells. | J Autoimmun | 2018 |
| 30259852 | Individualizing Care: Management Beyond Medical Therapy. | Clin Liver Dis | 2018 |
| 30005861 | Support of precision medicine through risk-stratification in autoimmune liver diseases - histology, scoring systems, and non-invasive markers. | Autoimmun Rev | 2018 |
| 30420264 | Prognostic models in primary biliary cholangitis. | J Autoimmun | 2018 |
| 30262398 | Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab. | Semin Oncol | 2018 |
| 30507971 | Amino acid residues in five separate HLA genes can explain most of the known associations between the MHC and primary biliary cholangitis. | PLoS Genet | 2018 |
| 27992413 | Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. | Nat Genet | 2017 |
| 28326584 | Editorial: scoring systems in primary biliary cholangitis - time to make a move. | Aliment Pharmacol Ther | 2017 |
| 28397694 | Stratified medicine and primary biliary cholangitis. | Lancet Gastroenterol Hepatol | 2017 |
| 29081991 | Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury. | ESMO Open | 2017 |
| 28818518 | Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. | Lancet Gastroenterol Hepatol | 2017 |
| 26223498 | The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. | Hepatology | 2016 |
| 27640331 | The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis. | Aliment Pharmacol Ther | 2016 |
| 27604637 | Early primary biliary cholangitis is characterised by brain abnormalities on cerebral magnetic resonance imaging. | Aliment Pharmacol Ther | 2016 |
| 27324985 | Toward precision medicine in primary biliary cholangitis. | Dig Liver Dis | 2016 |
| 26160476 | Making the most of new genetic risk factors - genetic and epigenetic fine mapping of causal autoimmune disease variants. | Clin Res Hepatol Gastroenterol | 2015 |
| 26394269 | International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. | Nat Commun | 2015 |
| 24626178 | Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver disease. | Cell Cycle | 2014 |
| 30992889 | Primary biliary cirrhosis: Family, genes, and bugs. | Clin Liver Dis (Hoboken) | 2014 |
| 23246637 | Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. | Gastroenterology | 2013 |